Suntharasamai P, Warrell M J, Warrell D A, Viravan C, Looareesuwan S, Supanaranond W, Chanthavanich P, Supapochana A, Tepsumethanon W, Pouradier-Duteil X
Lancet. 1986 Jul 19;2(8499):129-31. doi: 10.1016/s0140-6736(86)91946-x.
The protective effect of a new, potentially economical tissue-culture rabies vaccine, purified vero-cell rabies vaccine (PVRV), was tested in 106 patients bitten by animals with proven rabies. 0.5 ml PVRV was given intramuscularly on days 0, 3, 7, 14, 28, and 91; 47 patients with severe exposure were also given 20 IU/kg human rabies immune globulin (HRIG). All patients are alive and well after 1 year. Side-effects of treatment were negligible. Rabies neutralising antibody (greater than or equal to 1.6 IU) was demonstrated on day 14 and persisted for 1 year in every case. There was no significant suppression of the antibody response by HRIG. If the untreated mortality is 15%, PVRV is 81% efficient in protecting patients against rabies encephalitis (95% confidence limit). PVRV is likely to replace human diploid-cell strain vaccine as the most widely used tissue-culture rabies vaccine.
